Junning Cao
Shanghai Cancer Center · Fudan University · Fudan Universtiy Shanghai Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Junning Cao as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05467943 · Tazemetostat for the Treatment of Relapsed/Refractory Follicular LymphomaHutchmed · completed · Relapsed/Refractory Follicular Lymphoma With EZH2 · principal investigator
- Ph2NCT05257018 · R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS RelapseFudan University · recruiting · Diffuse Large B-cell Lymphoma · principal investigator
- Ph1/Ph2NCT05238064 · Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCLFudan University · unknown · PI3Kδ Inhibitor, Parsaclisib, CHOP · principal investigator
- Ph2NCT05189197 · A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double ExpressionFudan University · unknown · Diffuse Large B-cell Lymphoma(DLBCL) · principal investigator
- Ph2NCT04849351 · Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaHutchison Medipharma Limited · completed · Marginal Zone Lymphoma, Follicular Lymphoma · principal investigator
- Ph2NCT04512534 · Sintilimab Combined With Chidamide in Treating Peripheral T Cell LymphomaFudan University · recruiting · Peripheral T-cell Lymphoma · principal investigator
- Ph2NCT04164368 · Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma PatientsFudan University · completed · Double Expressor Lymphoma · principal investigator
- Ph1NCT03508011 · A Study of IMP4297 in Patients With Advanced Solid TumorsImpact Therapeutics, Inc. · completed · Advanced Solid Tumours, Breast Cancer, Ovarian Cancer · principal investigator
- Ph1NCT03231475 · Phase I Study of SPH1188-11 in NSCLCShanghai Pharmaceuticals Holding Co., Ltd · withdrawn · NSCLC Stage IIIB, NSCLC Stage IV · principal investigator
- Ph1NCT03128164 · A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care ExistedHutchison Medipharma Limited · completed · Lymphomas · principal investigator
- Ph1NCT03117101 · Study of the AL3810 in the Treatment of Advanced Solid TumorHaihe Biopharma Co., Ltd. · completed · Advanced Solid Tumors · principal investigator
- Ph1NCT02527746 · Study of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyEVIVE Biotechnology · completed · Neutropenia, Breast Cancer · principal investigator
- Ph1/Ph2NCT02522234 · A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyEVIVE Biotechnology · completed · Neutropenia · principal investigator
- Ph2/Ph3NCT01210287 · Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOPFudan University · unknown · Lymphoma · principal investigator
- Ph2NCT00974324 · Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell LymphomaFudan University · unknown · T Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:02 UTC. The ranking covers the 200 most relevant of 383 PubMed records, and a shared surname and initials can bring in a namesake. All 383 on PubMed
- CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.J Clin Invest · 20161,805 citationsRCR 53.6
- Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China).Circulation · 2016579 citationsRCR 21.4
- Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial.J Clin Oncol · 2019294 citationsRCR 12.4
- 252 citationsRCR 7.8
- 236 citationsRCR 9.5
- 212 citationsRCR 10.2
- Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.BMC Cancer · 2014192 citationsRCR 5.3
- Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.J Immunother Cancer · 2023137 citationsRCR 12.3
- A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma.Clin Cancer Res · 2019126 citationsRCR 4.0
- Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.J Clin Oncol · 2022121 citationsRCR 7.3